Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:2434-2440

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lüscher, T. F.
Right arrow Articles by Barton, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lüscher, T. F.
Right arrow Articles by Barton, M.
Related Collections
Right arrow Restenosis
Right arrow Cardiovascular Pharmacology
Right arrow Restenosis
Right arrow Pathophysiology
Right arrow Hypertension - basic studies
Right arrow Transplantation
Right arrow Acute myocardial infarction
Right arrow Chronic ischemic heart disease
Right arrow Mechanism of atherosclerosis/growth factors

(Circulation. 2000;102:2434.)
© 2000 American Heart Association, Inc.


Current Perspective

Endothelins and Endothelin Receptor Antagonists

Therapeutic Considerations for a Novel Class of Cardiovascular Drugs

Presented in part at the 71st Scientific Sessions of the American Heart Association, Dallas, Tex, November 9–12, 1998.

Thomas F. Lüscher, MD; Matthias Barton, MD

From the Department of Cardiology, University Hospital Zürich, and the Cardiovascular Research Laboratory, Institute of Physiology, University of Zürich, Switzerland.

Abstract—The 21-amino acid peptide endothelin-1 (ET-1) is the predominant isoform of the endothelin peptide family, which includes ET-2, ET-3, and ET-4. It exerts various biological effects, including vasoconstriction and the stimulation of cell proliferation in tissues both within and outside of the cardiovascular system. ET-1 is synthesized by endothelin-converting enzymes (ECE), chymases, and non-ECE metalloproteases; it is regulated in an autocrine fashion in vascular and nonvascular cells. ET-1 acts through the activation of Gi-protein–coupled receptors. ETA receptors mediate vasoconstriction and cell proliferation, whereas ETB receptors are important for the clearance of ET-1, endothelial cell survival, the release of nitric oxide and prostacyclin, and the inhibition of ECE-1.

ET is activated in hypertension, atherosclerosis, restenosis, heart failure, idiopathic cardiomyopathy, and renal failure. Tissue concentrations more reliably reflect the activation of the ET system because increased vascular ET-1 levels occur in the absence of changes in plasma. Experimental studies using molecular and pharmacological inhibition of the ET system and the first clinical trials have demonstrated that ET-1 takes part in normal cardiovascular homeostasis. Thus, ET-1 plays a major role in the functional and structural changes observed in arterial and pulmonary hypertension, glomerulosclerosis, atherosclerosis, and heart failure, mainly through pressure-independent mechanisms. ET antagonists are promising new agents in the treatment of cardiovascular diseases.


Key Words: atherosclerosis • restenosis • heart failure • hypertension • transplantation • nitric oxide




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
V. A. Rufanova, V. F. Pozdnev, E. I. Kalenikova, A. B. Postnikov, A. N. Storozhilova, V. P. Masenko, O. A. Gomazkov, O. S. Medvedev, and N. A. Medvedeva
Endothelin-Converting Enzyme Inhibition in the Rat Model of Acute Heart Failure: Heart Function and Neurohormonal Activation
Experimental Biology and Medicine, October 1, 2009; 234(10): 1201 - 1211.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
E. Larose, D. Behrendt, S. Kinlay, A. P. Selwyn, P. Ganz, and J. C. Fang
Endothelin-1 Is a Key Mediator of Coronary Vasoconstriction in Patients With Transplant Coronary Arteriosclerosis
Circ Heart Fail, September 1, 2009; 2(5): 409 - 416.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. A. Potenza, F. Addabbo, and M. Montagnani
Vascular actions of insulin with implications for endothelial dysfunction
Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E568 - E577.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. E. Kandalaft, A. Facciabene, R. J. Buckanovich, and G. Coukos
Endothelin B Receptor, a New Target in Cancer Immune Therapy
Clin. Cancer Res., July 15, 2009; 15(14): 4521 - 4528.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
A. Miyaki, S. Maeda, M. Yoshizawa, M. Misono, Y. Saito, H. Sasai, T. Endo, Y. Nakata, K. Tanaka, and R. Ajisaka
Effect of Weight Reduction With Dietary Intervention on Arterial Distensibility and Endothelial Function in Obese Men
Angiology, June 1, 2009; 60(3): 351 - 357.
[Abstract] [PDF]


Home page
Circ. Res.Home page
D. Marchant, Y. Dou, H. Luo, F. S. Garmaroudi, J. E. McDonough, X. Si, E. Walker, Z. Luo, A. Arner, R. G. Hegele, et al.
Bosentan Enhances Viral Load via Endothelin-1 Receptor Type-A-Mediated p38 Mitogen-Activated Protein Kinase Activation While Improving Cardiac Function During Coxsackievirus-Induced Myocarditis
Circ. Res., March 27, 2009; 104(6): 813 - 821.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. P. Comellas, A. Briva, L. A. Dada, M. L. Butti, H. E. Trejo, C. Yshii, Z. S. Azzam, J. Litvan, J. Chen, E. Lecuona, et al.
Endothelin-1 Impairs Alveolar Epithelial Function via Endothelial ETB Receptor
Am. J. Respir. Crit. Care Med., January 15, 2009; 179(2): 113 - 122.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. Peltonen, P. Taskinen, J. Napankangas, H. Leskinen, P. Ohtonen, Y. Soini, T. Juvonen, J. Satta, O. Vuolteenaho, and H. Ruskoaho
Increase in tissue endothelin-1 and ETA receptor levels in human aortic valve stenosis
Eur. Heart J., January 2, 2009; 30(2): 242 - 249.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. B. Mathews, N. Murugesan, J. Xia, U. Scheffel, J. Hilton, H. T. Ravert, R. F. Dannals, and Z. Szabo
Synthesis and In Vivo Evaluation of Novel PET Radioligands for Imaging the Endothelin-A Receptor
J. Nucl. Med., September 1, 2008; 49(9): 1529 - 1536.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
E. Raichlin, A. Prasad, V. Mathew, B. Kent, D. R. Holmes Jr, G. M. Pumper, R. E. Nelson, L. O. Lerman, and A. Lerman
Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis
Hypertension, September 1, 2008; 52(3): 522 - 528.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. L. Mundy, E. Haas, I. Bhattacharya, C. C. Widmer, M. Kretz, K. Baumann, and M. Barton
Endothelin stimulates vascular hydroxyl radical formation: effect of obesity
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2007; 293(6): R2218 - R2224.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
P. L. M. van Giersbergen, K. A. Gunawardena, and J. Dingemanse
Influence of Ethnic Origin and Sex on the Pharmacokinetics of Clazosentan
J. Clin. Pharmacol., November 1, 2007; 47(11): 1374 - 1380.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
C. Schindler
Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26.
[Abstract] [PDF]


Home page
HypertensionHome page
G. P. Van Guilder, C. M. Westby, J. J. Greiner, B. L. Stauffer, and C. A. DeSouza
Endothelin-1 Vasoconstrictor Tone Increases With Age in Healthy Men But Can Be Reduced by Regular Aerobic Exercise
Hypertension, August 1, 2007; 50(2): 403 - 409.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. Lattin, D. A. Zidar, K. Schroder, S. Kellie, D. A. Hume, and M. J. Sweet
G-protein-coupled receptor expression, function, and signaling in macrophages
J. Leukoc. Biol., July 1, 2007; 82(1): 16 - 32.
[Abstract] [Full Text] [PDF]


Home page
Poult. Sci.Home page
A. P. Gomez, M. J. Moreno, A. Iglesias, P. X. Coral, and A. Hernandez
Endothelin 1, its Endothelin Type A Receptor, Connective Tissue Growth Factor, Platelet-Derived Growth Factor, and Adrenomedullin Expression in Lungs of Pulmonary Hypertensive and Nonhypertensive Chickens
Poult. Sci., May 1, 2007; 86(5): 909 - 916.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. L. Mundy, E. Haas, I. Bhattacharya, C. C. Widmer, M. Kretz, R. Hofmann-Lehmann, R. Minotti, and M. Barton
Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity
Cardiovasc Res, January 15, 2007; 73(2): 368 - 375.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Merkus, O. Sorop, B. Houweling, F. Boomsma, A. H. van den Meiracker, and D. J. Duncker
NO and prostanoids blunt endothelin-mediated coronary vasoconstrictor influence in exercising swine
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2075 - H2081.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Gomberg-Maitland
Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better?
Eur. Respir. J., October 1, 2006; 28(4): 683 - 686.
[Full Text] [PDF]


Home page
CirculationHome page
G. Perez-Rivero, M. P. Ruiz-Torres, J. V. Rivas-Elena, M. Jerkic, M. L. Diez-Marques, J. M. Lopez-Novoa, M. A. Blasco, and D. Rodriguez-Puyol
Mice Deficient in Telomerase Activity Develop Hypertension Because of an Excess of Endothelin Production
Circulation, July 25, 2006; 114(4): 309 - 317.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
N. F. Kelland and D. J. Webb
Clinical Trials of Endothelin Antagonists in Heart Failure: A Question of Dose?
Experimental Biology and Medicine, June 1, 2006; 231(6): 696 - 699.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
C. C. Widmer, A. L. Mundy, M. Kretz, and M. Barton
Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries.
Experimental Biology and Medicine, June 1, 2006; 231(6): 777 - 781.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
D. Vetter, S. G. Shaw, R. P. Brandes, K. MuNter, W. Vetter, and M. Barton
Beneficial Cardiovascular Effects of Endothelin ETA Receptor Blockade in Established Long-Term Heart Failure After Myocardial Infarction.
Experimental Biology and Medicine, June 1, 2006; 231(6): 857 - 860.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
J. Ortmann, P. C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L. M. Terracciano, and M. Barton
Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1030 - 1033.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. He, J. Li, Y. Mu, R. Kuruba, Z. Ma, A. Wilson, S. Alber, Y. Jiang, T. Stevens, S. Watkins, et al.
Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells
Circ. Res., February 3, 2006; 98(2): 192 - 199.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
E. Thomson, P. Kumarathasan, P. Goegan, R. A. Aubin, and R. Vincent
Differential Regulation of the Lung Endothelin System by Urban Particulate Matter and Ozone
Toxicol. Sci., November 1, 2005; 88(1): 103 - 113.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Rodriguez-Vita, M. Ruiz-Ortega, M. Ruperez, V. Esteban, E. Sanchez-Lopez, J. J. Plaza, and J. Egido
Endothelin-1, via ETA Receptor and Independently of Transforming Growth Factor-{beta}, Increases the Connective Tissue Growth Factor in Vascular Smooth Muscle Cells
Circ. Res., July 22, 2005; 97(2): 125 - 134.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. M. Multani, J. S. Ikonomidis, P. Y. Kim, E. A. Miller, K. J. Payne, R. Mukherjee, B. H. Dorman, and F. G. Spinale
Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass
J. Thorac. Cardiovasc. Surg., March 1, 2005; 129(3): 584 - 590.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Barton
Ageing as a determinant of renal and vascular disease: role of endothelial factors
Nephrol. Dial. Transplant., March 1, 2005; 20(3): 485 - 490.
[Full Text] [PDF]


Home page
CirculationHome page
A. Lerman and A. M. Zeiher
Endothelial Function: Cardiac Events
Circulation, January 25, 2005; 111(3): 363 - 368.
[Full Text] [PDF]


Home page
Eur Respir JHome page
M.M. Hoeper and A.T. Dinh-Xuan
Combination therapy for pulmonary arterial hypertension: still more questions than answers
Eur. Respir. J., September 1, 2004; 24(3): 339 - 340.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. F. Leite-Moreira and C. Bras-Silva
Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1194 - H1199.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
K.-H. Ding, Q. Zhong, J. Xu, and C. M. Isales
Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells
Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E773 - E779.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. K. Kelly, S. Wedgwood, R. H. Steinhorn, and S. M. Black
Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase
Am J Physiol Lung Cell Mol Physiol, May 1, 2004; 286(5): L984 - L991.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Galie, A. Manes, and A. Branzi
The endothelin system in pulmonary arterial hypertension
Cardiovasc Res, February 1, 2004; 61(2): 227 - 237.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Carotti, F. Emma, S. Picca, E. Iannace, S. B. Albanese, M. Grigioni, F. Meo, M. Sciarra, and R. M. Di Donato
Inflammatory response to cardiac bypass in ewe fetuses: effects of steroid administration or continuous hemodiafiltration
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1839 - 1848.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
J. M Tovar and J. G Gums
Tezosentan in the Treatment of Acute Heart Failure
Ann. Pharmacother., December 1, 2003; 37(12): 1877 - 1883.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
W. M. Yarbrough, R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, R. E. Stroud, and F. G. Spinale
Direct inhibition of the sodium/hydrogen exchanger after prolonged regional ischemia improves contractility on reperfusion independent of myocardial viability
J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1489 - 1497.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
M. E. DiSanto
Corpus Cavernosum Smooth Muscle Physiology: A Role for Sex Hormones?
J Androl, November 1, 2003; 24(6_suppl): S6 - S16.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Merkus, B. Houweling, A. Mirza, F. Boomsma, A. H van den Meiracker, and D. J Duncker
Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation
Cardiovasc Res, September 1, 2003; 59(3): 745 - 754.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M.M. Hoeper, N. Taha, A. Bekjarova, R. Gatzke, and E. Spiekerkoetter
Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids
Eur. Respir. J., August 1, 2003; 22(2): 330 - 334.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
L. E. Spieker and T. F. Luscher
Endothelin receptor antagonists in heart failure--a refutation of a bold conjecture?
Eur J Heart Fail, August 1, 2003; 5(4): 415 - 417.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
K.-H. Ding, Q. Zhong, and C. M. Isales
Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1
Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E390 - E396.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
T. Plusczyk, B. Witzel, M. D. Menger, and M. Schilling
ETA and ETB receptor function in pancreatitis-associated microcirculatory failure, inflammation, and parenchymal injury
Am J Physiol Gastrointest Liver Physiol, June 9, 2003; 285(1): G145 - G153.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Wilkens, M. Bauer, N. Forestier, J. Konig, A. Eichler, S. Schneider, H.J. Schafers, and G.W. Sybrecht
Influence of Inhaled Iloprost on Transpulmonary Gradient of Big Endothelin in Patients With Pulmonary Hypertension
Circulation, March 25, 2003; 107(11): 1509 - 1513.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Li, G. D. Fink, S. W. Watts, C. A. Northcott, J. J. Galligan, P. J. Pagano, and A. F. Chen
Endothelin-1 Increases Vascular Superoxide via EndothelinA-NADPH Oxidase Pathway in Low-Renin Hypertension
Circulation, February 25, 2003; 107(7): 1053 - 1058.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. P. Rossi, C. Ganzaroli, M. Cesari, A. Maresca, M. Plebani, G. G. Nussdorfer, and A. C. Pessina
Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension
Cardiovasc Res, January 1, 2003; 57(1): 277 - 283.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. H. Petersen, J. Choy, B. Stauffer, F. Moien-Afshari, C. Aalkjaer, L. Leinwand, B. M. McManus, and I. Laher
Coronary artery myogenic response in a genetic model of hypertrophic cardiomyopathy
Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2244 - H2249.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
M. R. Dashwood and J. C. S. Tsui
Endothelins and the 'French Paradox': Are Detrimental Effects of Red Wine Also Associated with an Action on Endothelin Synthesis?
Angiology, November 1, 2002; 53(6): 749 - 751.
[PDF]


Home page
Eur Respir JHome page
N. Galie, A. Manes, and A. Branzi
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension
Eur. Respir. J., October 1, 2002; 20(4): 1037 - 1049.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J J V McMurray
Heart failure in 10 years time: focus on pharmacological treatment
Heart, October 1, 2002; 88(90002): ii40 - 46.
[Full Text] [PDF]


Home page
CirculationHome page
H. Ooi, W. S. Colucci, and M. M. Givertz
Endothelin Mediates Increased Pulmonary Vascular Tone in Patients With Heart Failure: Demonstration by Direct Intrapulmonary Infusion of Sitaxsentan
Circulation, September 24, 2002; 106(13): 1618 - 1621.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
R. A. Mangiafico, L. S. Malatino, T. Attina, R. Messina, and C. E. Fiore
Exaggerated Endothelin Release in Response to Acute Mental Stress in Patients with Intermittent Claudication
Angiology, July 1, 2002; 53(4): 383 - 390.
[Abstract] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
E. V. Balyakina, D. Chen, M. L. Lawrence, S. Manning, R. E. Parker, S. B. Shappell, and B. Meyrick
ET-1 receptor gene expression and distribution in L1 and L2 cells from hypertensive sheep pulmonary artery
Am J Physiol Lung Cell Mol Physiol, July 1, 2002; 283(1): L42 - L51.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
F. G. Spinale
The bioactive peptide endothelin causes multiple biologic responses relevant to myocardial and vascular performance after cardiac surgery
J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1031 - 1034.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin
New Treatments for Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
L. Ko, A. Maitland, P. W.M. Fedak, A. S. Dumont, M. Badiwala, F. Lovren, C. R. Triggle, T. J. Anderson, V. Rao, and S. Verma
Endothelin blockade potentiates endothelial protective effects of ace inhibitors in saphenous veins
Ann. Thorac. Surg., April 1, 2002; 73(4): 1185 - 1188.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R Sharma and S.D Anker
From tissue wasting to cachexia: changes in peripheral blood flow and skeletal musculature
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D12 - D17.
[Abstract] [PDF]


Home page
CirculationHome page
M. Bauer, H. Wilkens, F. Langer, S. O. Schneider, H. Lausberg, and H.-J. Schafers
Selective Upregulation of Endothelin B Receptor Gene Expression in Severe Pulmonary Hypertension
Circulation, March 5, 2002; 105(9): 1034 - 1036.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Martin, D. Ninio, and H. Krum
Effect of Endothelin Blockade on Basal and Stimulated Forearm Blood Flow in Patients With Essential Hypertension
Hypertension, March 1, 2002; 39(3): 821 - 824.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
W. Kiowski
The endothelin-type-A receptor in dilated cardiomyopathy: another key player?
Eur. Heart J., October 2, 2001; 22(20): 1849 - 1851.
[PDF]


Home page
Cardiovasc ResHome page
M. Barton and B. Glodny
Endothelin receptor blockade and nitric oxide bioactivity: [Cardiovascular Research 2001;49:146-151]
Cardiovasc Res, October 1, 2001; 52(1): 161 - 163.
[Full Text] [PDF]


Home page
Eur Heart JHome page
A. Gaspardone
Endothelin: a new marker of risk of rapid coronary stenosis progression in patients with stable angina?
Eur. Heart J., September 1, 2001; 22(17): 1519 - 1520.
[PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. J. Wort, M. Woods, T. D. Warner, T. W. Evans, and J. A. Mitchell
Endogenously Released Endothelin-1 from Human Pulmonary Artery Smooth Muscle Promotes Cellular Proliferation . Relevance to Pathogenesis of Pulmonary Hypertension and Vascular Remodeling
Am. J. Respir. Cell Mol. Biol., July 1, 2001; 25(1): 104 - 110.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
E. Braunwald
Congestive heart failure: a half century perspective
Eur. Heart J., May 2, 2001; 22(10): 825 - 836.
[PDF]


Home page
Cardiovasc ResHome page
F. Duru, M. Barton, T. F. Luscher, and R. Candinas
Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?
Cardiovasc Res, February 1, 2001; 49(2): 272 - 280.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
S. D.R. Thackray, K. K.A. Witte, A. Khand, A. Dunn, A. L. Clark, and J. G.F. Cleland
Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure
Eur J Heart Fail, January 1, 2001; 3(1): 117 - 124.
[Abstract] [Full Text] [PDF]